GlobeNewswire Inc.May 26, 1:00 PM ET▲ Positive
Advancing SGT-003, a Phase III gene transference therapy, representing significant progress in late-stage DMD clinical development.
Solid Biosciences news
$7.16−1.65%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Solid Biosciences
No recent articles focused on Solid Biosciences.
Also mentions SLDB
Articles that tag SLDB but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology